Risultati per: Dieta per Acne

Report Aletheia, eccesso cibi ultra-formulati. Partire da scuole

Studio, se seguita per anni anche -25% probabilita’ di Alzheimer

-37%rischio morte con esercizio fisico.Banditi cibi infiammatori

This case report describes a woman in her 50s who was initially diagnosed with palmoplantar pustulosis but was subsequently found to have synovitis, acne, pustulosis, hyperstosis, and osteitis syndrome, which was successfully treated with abrocitinib.

This case report describes 2 patients who received off-label bimekizumab for treatment-resistent acne conglobata.

Dalla Ragione, non solo anoressia e bulimia

Il 15% trova difficili da reperire gli alimenti previsti

At-home light-emitting diode (LED) devices are trending on social media as a new way to treat acne, with the red and blue lights thought to target bacteria and reduce inflammation. A recent study in JAMA Dermatology suggests they could be both safe and effective, although additional research is needed to confirm this.

This systematic review and meta-analysis examines 6 studies to determine the safety and efficacy of different types of at-home light-emitting diode devices in reducing acne lesions.

Introduction
Acne scarring is one of the primary sequelae that affect patients with acne, with facial scarring occurring to some extent in 95% of patients with active acne. Subtypes include atrophic, hypertrophic and keloid scarring. Treatment options include topical and surgical approaches. Despite numerous clinical trials focusing on acne scarring treatments, the absence of standardised outcome reporting across these trials raises concerns in evaluating treatment methods. To address this issue, this project aims to develop a core set of outcomes which should be uniformly assessed in all clinical trials involving acne scarring.

Methods and analysis
Outcomes will be extracted from four sources: a systematic literature review, patient interviews, printed and electronic sources and stakeholder involvement. The steering committee will assess the potential outcomes, adding or removing outcomes if needed. The Delphi process will be performed to understand the importance of outcomes. Two rounds of Delphi surveys will be completed by physicians, researchers and patients. Following this, a consensus meeting involving stakeholders will be held to refine the outcomes based on participant scores. The meeting will end in a voting process to determine a final recommended core outcome set (COS). This study will be conducted in collaboration with the Core Outcome Measures in Effectiveness Trials (COMET) initiative and the CHORD COUSIN Collaboration (C3). This study aims to develop a global COS to standardise assessment approaches in clinical trials of acne scarring. The final goal is to enhance uniformity of outcome reporting.

Ethics and dissemination
Ethical approval and consent to participate for the study have been granted by Northwestern University Institutional Review Board protocol ID: STU00097285. On completion of the COS, we plan to publish our results in peer-reviewed journals and send participants the finalised COS.

PROSPERO registration details
This study is registered with PROSPERO (CRD42023460964), COMET (754) and C3 (https://www.c3outcomes.org/improved-acne-scarring).

This cohort study assess rates of acne relapse and isotretinoin retrial and identifies associated factors in patients after completing an isotretinoin course.

Presentato studio alla Festa del Bio-MontagnaMadre

Essenziali frutta, verdura e olio evo. Si riduce l’infiammazione sistemica

Prime linee guida da Iss e 20 società scientifiche

Objectives
To identify what changes in the prescribing of isotretinoin have occurred since funded prescriber access was widened in 2009 from ‘dermatologist only’ prescribing to include ‘general practitioners (GPs) and nurse practitioners working within their scope of practice’.

Design
Evaluation of isotretinoin dispensing data from 2008 to 2023 using the national annual prescribing data obtained from the New Zealand Pharmaceutical National Collection database.

Setting
All New Zealand citizens prescribed and dispensed funded isotretinoin for acne from 2008 to 2023 were included.

Main outcome measures
The prescribing data were analysed to identify the total number of prescriptions per year by prescribing clinician type, patient ethnicity and deprivation levels.

Results
In 2008, nearly 100% (26897) of dispensed prescriptions were written by a dermatologist, while in 2023, 79% (39432) were written by primary care clinicians. Annual isotretinoin prescriptions increased by 87%, from 26 897 (2008) to 50613 (2023). Prescriptions for Māori increased from 1750 in 2008 to 4374 in 2023, with similar increases for other ethnic minorities.

Conclusion
Expanding the prescriber cohort has resulted in a substantial increase in prescriptions, with primary care now issuing the majority of isotretinoin prescriptions. These data demonstrate that the GP workforce can absorb and manage the additional acne workload from the increasing population. Enhanced access for patients suggests an unmet need. An absolute number of prescriptions have risen faster for Māori and Asian patients than for Europeans. Pacific people were generally lower than Europeans. This suggests the longstanding ethnic disparity in access to isotretinoin is partially reduced.
Many countries have restrictions on patient access to isotretinoin, similar to New Zealand in 2008. This is the first study demonstrating that, given appropriate postgraduate education and support, the isotretinoin risk–benefit profile may be enhanced to safely deliver high-quality, timely, equitable patient access to isotretinoin in primary care.